Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
- AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
- Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
- (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
- Recent corporate highlights include the following:
In January 2024, we completed a dividend distribution of common stock warrants to shareholders.